Type 2 Diabetes Mellitus [2016]: Bulletin #3
This edition presents key opinion leader (KOL) views on recent developments in the type 2 diabetes mellitus market. Topics covered include: AstraZeneca’s announcement of positive top-line results from the Phase IIIb/IV EXSCEL study evaluating the effect of once-weekly Bydureon versus placebo in type-2 diabetics; the FDA’s boxed warning on risks of foot amputations for Johnson & Johnson’s canagliflozin (Invokana/Invokamet) based on data from the CANVAS and CANVAS-R trials; and EnteroMedics reporting of three-year data from its VBloc DM2 study in obese type 2 diabetics.
Business Questions
Business Questions
- How do KOLs view the data for AstraZeneca’s EXSCEL study for Bydureon?
- Bydureon did not show superiority for cardiovascular end-point; will it have a role in type 2 diabetes treatment algorithm? If so where?
- How do KOLs see Bydureon in relation to Trulicity and other GLP-1s?
- How do KOLs see the FDA’s boxed warning for canagliflozin?
- How do KOLs rate Invokana and other SGLT-2 inhibitors?
- What potential do KOLs think EnteroMedics vBloc implant device and what challenges do they foresee?
- Will vBloc find a role in the treatment of diabetic patients?
